| 2010 Guide to the Life Sciences Industry for | | | | continue if changes are not made to the cherished |
| Technology Providers | | | | blockbuster model. A fundamental step in |
| As drug sales drop and pressures to fill the | | | | transitioning from this model is to adopt |
| product pipelines rise, executives are becoming | | | | technologies that will aid in streamlining processes |
| more open-minded about the use of IT solutions. | | | | throughout the drug lifecycle and increasing |
| However, without the proper industry | | | | R&D productivity. |
| background, it can be difficult for technology | | | | As pressures grow to fill their dwindling product |
| vendors to enter this conservative market. This | | | | pipelines with innovative drugs, pharma companies |
| brief provides an overview of the life sciences | | | | are embracing biotechnology, biomedical research |
| industry in order for vendors to understand how | | | | and the concept of personalized medicine. This has |
| to enter this market. ( ) | | | | led to a greater demand for innovative |
| Scope | | | | developments from the IT sector to provide the |
| * Offers an overview of the pharmaceutical and | | | | biotech industry with the tools it requires. |
| biotechnology sectors | | | | The industry is known to be conservative and |
| * Discusses key areas where there is greatest | | | | skeptical of commercial technologies. Historically |
| need for technology in the life sciences industry | | | | companies built their own solutions, resulting in |
| * Provides go-to-market strategies to help enter | | | | legacy systems that are difficult to maintain and |
| the pharma and biotech markets and be | | | | integrate with new systems. Executives are |
| successful | | | | beginning to understand the benefits of |
| Highlights | | | | pharma-specific solutions, but need time, education |
| The life sciences industry has been experiencing | | | | and convincing. |
| slower growth in recent years, a trend that will | | | | |